Illuminating biomarkers: Metal-based strategies and fluorescence nanosensors for clinical monitoring.

Plasmonic and fluorescence nanosensors have become vital tools for recent diagnostic applications due to their great sensitivity, rapid response, and capacity to determine very small amounts of biological targets. Plasmonic sensors rely on localized surface plasmon resonance (LSPR), which occurs when metallic nanostructures, such as gold or silver nanoparticles, generate strong electromagnetic fields on their surfaces. This phenomenon enables sensors to detect changes produced by biomarker or pathogen binding with great accuracy and precision. Recent advances in nanoparticle design and surface modification have improved their selectivity and appropriateness for point-of-care diagnostic devices. On the other hand, fluorescence nanosensors measure changes in fluorescence wavelength or intensity when a target analyte interacts with a fluorescent probe. Advanced fluorescent nanomaterials, including quantum dots, carbon dots, MOF-based fluorophores, and organic dyes, have significantly increased signal stability, biocompatibility, and detection limits. These developments have allowed for the sensitive determination of disease-related analytes such as nucleic acids, proteins, and metabolites. Furthermore, approaches like aggregation-induced emission and fluorescence resonance energy transfer (FRET) have improved the capabilities of fluorescence-based sensing platforms. Both plasmonic and fluorescence nanosensors provide reliable, fast, and simple diagnostic options for early illness diagnosis and clinical monitoring. This review focuses on the operating principles of both approaches, current advances in material design, and their expanding importance in diagnostic applications. This review provides a thorough resource that can successfully support and progress further research and developments in the field, particularly with regard to the applications of comparable nanosensors.